Warken pushes for improvement in care for Long-Covid patients - Long Covid patients still wait for approved treatments in the EU

Long Covid remains without an approved treatment in Germany and the EU. Researchers and doctors continue to search for solutions, but gaps in understanding the condition slow progress. Nina Warken, a leading expert, has called for faster action to bring relief to patients struggling with lingering symptoms.

Currently, no medication has been officially approved for long Covid. The challenge lies in defining the illness and uncovering its origins. Without this foundation, developing targeted treatments remains difficult.

Nina Warken stresses the importance of fundamental research to create effective therapies. Yet, she also urges a shift in focus: getting existing medications to patients more quickly. Repurposed drugs like Famotidin, Loratadin, and Colchicin are already being tested in clinical trials. The British STIMULATE-ICP study and Germany's National Decade Against Post-Infectious Diseases, launched in November 2025, are key efforts in this direction.

The German initiative, backed by €500 million in funding, aims to speed up research and testing. Warken plans to strengthen discussions with medical professionals and researchers. Her goal is to improve diagnosis methods and patient care for those affected by long Covid.

While clinical trials explore potential treatments, patients still lack approved options. The €500 million investment in Germany's research programme signals a structured push for answers. For now, experts like Warken are working to bridge the gap between research and real-world care.